肿瘤细胞治疗研究
英文原题：Novel Cellular Therapies for Hepatocellular Carcinoma.
肝细胞癌 (HCC) 是全球癌症相关死亡的主要原因之一。
肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一。多数患者确诊时已处于晚期，目前以酪氨酸激酶抑制剂或免疫检查点抑制剂（ICI）为主的标准治疗仅带来有限临床获益。针对HCC的细胞免疫疗法目前正在实验室和临床试验中评估。本文综述HCC细胞免疫疗法的发展格局，界定抗原靶点，概述用于HCC的各类细胞治疗产品（如CAR-T和TCR-T），并探讨先进工程化策略如何进一步增强这一治疗方法。
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers modest clinical benefit. Cellular immune therapies targeting HCC are currently being tested in the laboratory and in clinical trials. Here, we review the landscape of cellular immunotherapy for HCC, defining antigenic targets, outlining the range of cell therapy products being applied in HCC (such as CAR-T and TCR-T), and exploring how advanced engineering solutions may further enhance this therapeutic approach.
MEMBER ACCOUNT
登录成功会直接打开下一页。
